应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
HALO 奥洛兹美医疗
盘后交易 08-15 16:19:08 EDT
59.10
+1.69
+2.94%
盘后
59.10
+0.00
0.00%
16:18 EDT
最高
59.15
最低
57.41
成交量
174.05万
今开
58.09
昨收
57.41
日振幅
3.04%
总市值
74.87亿
流通市值
74.07亿
总股本
1.27亿
成交额
1.02亿
换手率
1.39%
流通股本
1.25亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
奥洛兹美医疗2024财年第二财季实现净利润93.25百万美元,同比增加24.75%
自选股智能写手 · 08-12
奥洛兹美医疗2024财年第二财季实现净利润93.25百万美元,同比增加24.75%
奥洛兹美医疗盘中异动 下午盘股价大涨5.00%
自选股智能写手 · 07-17
奥洛兹美医疗盘中异动 下午盘股价大涨5.00%
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由65.
智通财经 · 06-24
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由65.
富国银行:维持Halozyme Therapeutics(HALO.US)评级,由增持调整至增持评级, 目标价由48.00美元调整至58.
智通财经 · 06-07
富国银行:维持Halozyme Therapeutics(HALO.US)评级,由增持调整至增持评级, 目标价由48.00美元调整至58.
HC Wainwright & Co.:维持Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.
智通财经 · 06-07
HC Wainwright & Co.:维持Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.
Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级由增持调整至中性评级, 目标价由48.
智通财经 · 06-07
Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级由增持调整至中性评级, 目标价由48.
Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级,由增持调整至中性评级, 目标价由48.
智通财经 · 06-07
Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级,由增持调整至中性评级, 目标价由48.
成分股Ventyx Biosciences收跌37.78%,该公司宣布,VTX3232临床前数据体现出积极的减肥效果——受试对象的肥胖症出现逆转、心血管代谢功能出现改善,下半年将对受试对象启动2a临床试验,然而,华尔街认为这样的结果是让人感到失望的,奥本海默分析师Jeff Jones给予超配评级,目标价从12美元下调至10美元。
华尔街见闻 · 06-07
成分股Ventyx Biosciences收跌37.78%,该公司宣布,VTX3232临床前数据体现出积极的减肥效果——受试对象的肥胖症出现逆转、心血管代谢功能出现改善,下半年将对受试对象启动2a临床试验,然而,华尔街认为这样的结果是让人感到失望的,奥本海默分析师Jeff Jones给予超配评级,目标价从12美元下调至10美元。
奥洛兹美医疗盘中异动 早盘急速拉升5.77%
自选股智能写手 · 06-06
奥洛兹美医疗盘中异动 早盘急速拉升5.77%
BUZZ-Halozyme Therapeutics 因上调年度预期而上涨
Reuters · 06-06
BUZZ-Halozyme Therapeutics 因上调年度预期而上涨
奥洛兹美医疗股价在盘前交易中上涨5.5%公司上调了财年营业收入和利润预测。
智通财经 · 06-06
奥洛兹美医疗股价在盘前交易中上涨5.5%公司上调了财年营业收入和利润预测。
美国研究综述-和弦能源、PVH、Saia
Reuters · 06-06
美国研究综述-和弦能源、PVH、Saia
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.
智通财经 · 06-04
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.
摩根大通证券公司:维持Halozyme Therapeutics(HALO.US)评级,由优于大市调整至优于大市评级, 目标价由72.00美元调整至71.00美元。
智通财经 · 05-09
摩根大通证券公司:维持Halozyme Therapeutics(HALO.US)评级,由优于大市调整至优于大市评级, 目标价由72.00美元调整至71.00美元。
奥洛兹美医疗盘中异动 早盘股价大涨5.06%报43.30美元
自选股智能写手 · 05-08
奥洛兹美医疗盘中异动 早盘股价大涨5.06%报43.30美元
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.00美元。
智通财经 · 05-08
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.00美元。
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.
智通财经 · 04-17
HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.
Halozyme Therapeutics(HALO.US)获TD Cowen首次覆盖,给予优于大市评级, 目标价54.00美元。
智通财经 · 02-29
Halozyme Therapeutics(HALO.US)获TD Cowen首次覆盖,给予优于大市评级, 目标价54.00美元。
奥洛兹美医疗2023财年实现净利润2.82亿美元,同比增加39.60%
自选股智能写手 · 02-23
奥洛兹美医疗2023财年实现净利润2.82亿美元,同比增加39.60%
奥洛兹美医疗盘中异动 早盘股价大涨5.18%报37.86美元
自选股智能写手 · 02-21
奥洛兹美医疗盘中异动 早盘股价大涨5.18%报37.86美元
公司概况
公司名称:
奥洛兹美医疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
Halozyme Therapeutics, Inc.是一家生物制药公司,成立于1998年。2007年11月,该公司重组并注册于特拉华州(以前注册于内华达州)。该公司致力于创新产品的开发和商业化。公司研究细胞外基质、细胞外区域,包括细胞迁移、信号和存活。多年来,该公司已经开发了独特的科学专业知识, 允许其追求侧重于环境发展的治疗办法。
发行价格:
--
{"stockData":{"symbol":"HALO","market":"US","secType":"STK","nameCN":"奥洛兹美医疗","latestPrice":59.1,"timestamp":1723752000000,"preClose":57.41,"halted":0,"volume":1740496,"hourTrading":{"tag":"盘后","latestPrice":59.1,"preClose":59.1,"latestTime":"16:18 EDT","volume":25827,"amount":1526375.9582699998,"timestamp":1723753085856},"delay":0,"floatShares":125331575,"shares":126678280,"eps":2.584198,"marketStatus":"盘后交易","marketStatusCode":4,"change":1.69,"latestTime":"08-15 16:19:08 EDT","open":58.09,"high":59.15,"low":57.405,"amount":102139329.921856,"amplitude":0.030395,"askPrice":59.25,"askSize":1,"bidPrice":56.5,"bidSize":300,"shortable":3,"etf":0,"ttmEps":2.584198,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1723766400000},"adr":0,"listingDate":1099285200000,"adjPreClose":57.41,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":58.09,"preClose":57.41,"latestTime":"09:29 EDT","volume":1281,"amount":74408.300505,"timestamp":1723728599999},"postHourTrading":{"tag":"盘后","latestPrice":59.1,"preClose":59.1,"latestTime":"16:18 EDT","volume":25827,"amount":1526375.9582699998,"timestamp":1723753085856},"volumeRatio":1.471811,"impliedVol":0.301,"impliedVolPercentile":0.0357},"requestUrl":"/m/hq/s/HALO/wiki","defaultTab":"wiki","newsList":[{"id":"2458697815","title":"奥洛兹美医疗2024财年第二财季实现净利润93.25百万美元,同比增加24.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458697815","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458697815?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:16","pubTimestamp":1723392994,"startTime":"0","endTime":"0","summary":"8月12日,奥洛兹美医疗公布财报,公告显示公司2024财年第二财季净利润为93.25百万美元,同比增加24.75%;其中营业收入为2.31亿美元,同比增加4.52%,每股基本收益为0.73美元。从资产负债表来看,奥洛兹美医疗总负债16.80亿美元,其中短期债务30.66百万美元,资产负债比为1.18,流动比率为7.43。机构评级:截至2024年8月12日,当前有10家机构对奥洛兹美医疗目标价做出预测,其中目标均价为59.10美元,其中最低目标价为48.00美元,最高目标价为72.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200164695904669&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200164695904669&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO"],"gpt_icon":0},{"id":"2452949391","title":"奥洛兹美医疗盘中异动 下午盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452949391","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452949391?lang=zh_cn&edition=full","pubTime":"2024-07-17 02:36","pubTimestamp":1721154970,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日02时36分,奥洛兹美医疗股票出现异动,股价急速拉升5.00%。截至发稿,该股报55.18美元/股,成交量93.771万股,换手率0.74%,振幅4.94%。奥洛兹美医疗股票所在的生物技术行业中,整体涨幅为0.13%。奥洛兹美医疗公司简介:奥洛兹美医疗有限公司是一家专注于开发和商业化新型肿瘤治疗的生物技术公司。奥洛兹美专注于在医疗需求未得到满足的治疗领域开发其专利产品,重点是肿瘤学,并将其技术授权给生物制药公司合作开发产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717023611941f7827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717023611941f7827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BK4139","HALO"],"gpt_icon":0},{"id":"2445909029","title":"HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由65.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445909029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445909029?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:09","pubTimestamp":1719223766,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HALO","LU0053671581.USD","BK4139","LENZ"],"gpt_icon":0},{"id":"2441068444","title":"富国银行:维持Halozyme Therapeutics(HALO.US)评级,由增持调整至增持评级, 目标价由48.00美元调整至58.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441068444","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441068444?lang=zh_cn&edition=full","pubTime":"2024-06-07 20:39","pubTimestamp":1717763943,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0053671581.USD","HALO","LENZ","BK4139"],"gpt_icon":0},{"id":"2441031051","title":"HC Wainwright & Co.:维持Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441031051","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441031051?lang=zh_cn&edition=full","pubTime":"2024-06-07 19:13","pubTimestamp":1717758788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","HALO","LU0053671581.USD","LENZ"],"gpt_icon":0},{"id":"2441037907","title":"Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级由增持调整至中性评级, 目标价由48.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441037907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441037907?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:21","pubTimestamp":1717752069,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0053671581.USD","HALO","BK4139","LENZ"],"gpt_icon":0},{"id":"2441636037","title":"Piper Sandler:下调Halozyme Therapeutics(HALO.US)评级,由增持调整至中性评级, 目标价由48.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441636037","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441636037?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:19","pubTimestamp":1717751994,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","HALO","LENZ","LU0053671581.USD"],"gpt_icon":0},{"id":"2441773690","title":"成分股Ventyx Biosciences收跌37.78%,该公司宣布,VTX3232临床前数据体现出积极的减肥效果——受试对象的肥胖症出现逆转、心血管代谢功能出现改善,下半年将对受试对象启动2a临床试验,然而,华尔街认为这样的结果是让人感到失望的,奥本海默分析师Jeff Jones给予超配评级,目标价从12美元下调至10美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2441773690","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441773690?lang=zh_cn&edition=full","pubTime":"2024-06-07 05:56","pubTimestamp":1717710965,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["LU0053671581.USD","BK4139","LXRX","ILMN","HALO","BK4121","BK4535","BK1576","NUVL","BK4534","BK1583","BK4007","ERAS","VTYX","03347","BK4539","BK1141","BK4548","BK4585","BK4588"],"gpt_icon":0},{"id":"2441710135","title":"奥洛兹美医疗盘中异动 早盘急速拉升5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441710135","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441710135?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:33","pubTimestamp":1717680781,"startTime":"0","endTime":"0","summary":"北京时间2024年06月06日21时33分,奥洛兹美医疗股票出现异动,股价大幅拉升5.77%。奥洛兹美医疗股票所在的生物技术行业中,整体涨幅为0.02%。奥洛兹美医疗公司简介:奥洛兹美医疗有限公司是一家专注于开发和商业化新型肿瘤治疗的生物技术公司。消息层面,截至21时33分,《富国集团维持奥洛兹美医疗买入评级,维持目标价48美元》资讯为影响奥洛兹美医疗的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406062133019f20cf8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406062133019f20cf8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2441712240","title":"BUZZ-Halozyme Therapeutics 因上调年度预期而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2441712240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441712240?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:29","pubTimestamp":1717680541,"startTime":"0","endTime":"0","summary":" 6月6日 - ** 生物制药公司Halozyme Therapeutics 股价在盘前交易中上涨6.9%,报48.81美元。** 公司上调24财年营收预期至9.35亿至10.2亿美元,而之前的预期为9.15亿至9.85亿美元,主要受特许权使用费收入和产品销售额增长的推动。** 光环公司预计 24 财年每股收益介于 3.65 美元至 4.05 美元之间,之前预计为 3.55 美元至 3.90 美元。** 公司表示,根据其 Enhanze 药物传输技术获得欧洲专利的情况,公司将上调年度预期。** 哈洛公司预计特许权使用费收入将达到 5.2 亿至 5.55 亿美元,比上年增长 16% 至 24%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","HALO","BUZZ","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2441954714","title":"奥洛兹美医疗股价在盘前交易中上涨5.5%公司上调了财年营业收入和利润预测。","url":"https://stock-news.laohu8.com/highlight/detail?id=2441954714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441954714?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:08","pubTimestamp":1717679330,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2441661207","title":"美国研究综述-和弦能源、PVH、Saia","url":"https://stock-news.laohu8.com/highlight/detail?id=2441661207","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441661207?lang=zh_cn&edition=full","pubTime":"2024-06-06 15:13","pubTimestamp":1717658029,"startTime":"0","endTime":"0","summary":" 路透6月6日 - 华尔街证券分析师周四调整了对 Chord Energy、PVH 和 Saia 等几家美国上市公司的评级和目标价。* 好市多批发公司 :奥本海默将目标价从850美元上调至905美元 * PVH Corp :巴克莱将目标价从149美元上调至154美元 * Saia Inc :TD Cowen将目标价从473美元上调至475美元 * Take-Two Interactive Software Inc :摩根大通将目标价从180美元上调至200美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FERG","LU1951200564.SGD","CHPT","APH","COST","PAVM","HPE","BK4211","LU2125154935.USD","SNOW","IE00B894F039.SGD","CHRD","LU0566484027.USD","LU2272731782.SGD","LU2286300806.USD","PVH","MD","SHC","ILMN","LUCD","DLTR","PBR","CRWD","SAIA","UNFI","WMT","XYL","VRNT","LU0289960550.SGD","HALO","LU0498741114.HKD","TTWO","LU2092937221.SGD","IE00BZ1G4Q59.USD","SSRM","VBNK","VIR","LU1951198990.SGD","SMAR","BK4581","BK4504","INSM","BK4505","SITE","LU1559883803.SGD","CXM","OLLI","LAAC","BK4542","BASE"],"gpt_icon":0},{"id":"2440228339","title":"HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价由50.","url":"https://stock-news.laohu8.com/highlight/detail?id=2440228339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440228339?lang=zh_cn&edition=full","pubTime":"2024-06-04 18:28","pubTimestamp":1717496888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"2434317772","title":"摩根大通证券公司:维持Halozyme Therapeutics(HALO.US)评级,由优于大市调整至优于大市评级, 目标价由72.00美元调整至71.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434317772","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434317772?lang=zh_cn&edition=full","pubTime":"2024-05-09 02:05","pubTimestamp":1715191519,"startTime":"0","endTime":"0","summary":"摩根大通证券公司:维持Halozyme Therapeutics(HALO.US)评级,由优于大市调整至优于大市评级, 目标价由72.00美元调整至71.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050902052387e13df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050902052387e13df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO","LENZ"],"gpt_icon":0},{"id":"2433219077","title":"奥洛兹美医疗盘中异动 早盘股价大涨5.06%报43.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433219077","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433219077?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:32","pubTimestamp":1715175162,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日21时32分,奥洛兹美医疗股票出现波动,股价快速拉升5.06%。截至发稿,该股报43.30美元/股,成交量5.9176万股,换手率0.05%,振幅5.23%。奥洛兹美医疗股票所在的生物技术行业中,整体涨幅为0.32%。奥洛兹美医疗公司简介:奥洛兹美医疗有限公司是一家专注于开发和商业化新型肿瘤治疗的生物技术公司。该信息摘要如下:HC Wainwright & Co.:重申Halozyme Therapeutics评级,由买入调整至买入评级, 目标价50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050821324279268a21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050821324279268a21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2433437747","title":"HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433437747","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433437747?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:36","pubTimestamp":1715168215,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050819365787e04e65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050819365787e04e65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO","LENZ"],"gpt_icon":0},{"id":"2428328609","title":"HC Wainwright & Co.:重申Halozyme Therapeutics(HALO.US)评级,由买入调整至买入评级, 目标价50.","url":"https://stock-news.laohu8.com/highlight/detail?id=2428328609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2428328609?lang=zh_cn&edition=full","pubTime":"2024-04-17 23:40","pubTimestamp":1713368450,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","HALO","LU0053671581.USD","LENZ"],"gpt_icon":0},{"id":"2415651747","title":"Halozyme Therapeutics(HALO.US)获TD Cowen首次覆盖,给予优于大市评级, 目标价54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2415651747","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2415651747?lang=zh_cn&edition=full","pubTime":"2024-02-29 19:59","pubTimestamp":1709207962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4207","HALO","TD","LU0053671581.USD","BK4566","BK4585"],"gpt_icon":0},{"id":"2413462592","title":"奥洛兹美医疗2023财年实现净利润2.82亿美元,同比增加39.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413462592","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413462592?lang=zh_cn&edition=full","pubTime":"2024-02-23 00:26","pubTimestamp":1708619209,"startTime":"0","endTime":"0","summary":"12月31日,奥洛兹美医疗公布财报,公告显示公司2023财年净利润为2.82亿美元,同比增加39.60%;其中营业收入为8.29亿美元,同比增加25.61%,每股基本收益为2.13美元。从资产负债表来看,奥洛兹美医疗总负债16.49亿美元,其中短期债务32.20百万美元,资产负债比为1.06,流动比率为6.67。机构评级:截至2023年12月31日,当前有10家机构对奥洛兹美医疗目标价做出预测,其中目标均价为48.10美元,其中最低目标价为28.00美元,最高目标价为72.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022300265587afb30f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022300265587afb30f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO"],"gpt_icon":0},{"id":"2413422955","title":"奥洛兹美医疗盘中异动 早盘股价大涨5.18%报37.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413422955","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413422955?lang=zh_cn&edition=full","pubTime":"2024-02-21 22:30","pubTimestamp":1708525846,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日22时30分,奥洛兹美医疗股票出现异动,股价快速上涨5.18%。截至发稿,该股报37.86美元/股,成交量5.7927万股,换手率0.05%,振幅0.50%。最近的财报数据显示,该股实现营业收入8.29亿美元,净利润2.82亿美元,每股收益2.13美元,毛利5.63亿美元,市盈率18.03倍。奥洛兹美医疗股票所在的生物技术行业中,整体涨幅为0.00%。奥洛兹美医疗公司简介:奥洛兹美医疗公司是一家专注于开发和商业化新型肿瘤治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221223046791322d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221223046791322d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.halozyme.com","stockEarnings":[{"period":"1week","weight":0.0608},{"period":"1month","weight":0.0925},{"period":"3month","weight":0.2648},{"period":"6month","weight":0.5903},{"period":"1year","weight":0.3042},{"period":"ytd","weight":0.5533}],"compareEarnings":[{"period":"1week","weight":0.0484},{"period":"1month","weight":-0.0317},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0886},{"period":"1year","weight":0.2277},{"period":"ytd","weight":0.144}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Halozyme Therapeutics, Inc.是一家生物制药公司,成立于1998年。2007年11月,该公司重组并注册于特拉华州(以前注册于内华达州)。该公司致力于创新产品的开发和商业化。公司研究细胞外基质、细胞外区域,包括细胞迁移、信号和存活。多年来,该公司已经开发了独特的科学专业知识, 允许其追求侧重于环境发展的治疗办法。","yearOnYearQuotes":[{"month":1,"riseRate":0.45,"avgChangeRate":-0.018251},{"month":2,"riseRate":0.6,"avgChangeRate":0.02437},{"month":3,"riseRate":0.5,"avgChangeRate":0.041397},{"month":4,"riseRate":0.619048,"avgChangeRate":-0.004965},{"month":5,"riseRate":0.571429,"avgChangeRate":0.009472},{"month":6,"riseRate":0.619048,"avgChangeRate":0.049232},{"month":7,"riseRate":0.619048,"avgChangeRate":0.029387},{"month":8,"riseRate":0.47619,"avgChangeRate":-0.021819},{"month":9,"riseRate":0.35,"avgChangeRate":0.027274},{"month":10,"riseRate":0.5,"avgChangeRate":-0.019234},{"month":11,"riseRate":0.65,"avgChangeRate":0.069974},{"month":12,"riseRate":0.6,"avgChangeRate":0.124665}],"exchange":"NASDAQ","name":"奥洛兹美医疗","nameEN":"Halozyme Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥洛兹美医疗,HALO,奥洛兹美医疗股票,奥洛兹美医疗股票老虎,奥洛兹美医疗股票老虎国际,奥洛兹美医疗行情,奥洛兹美医疗股票行情,奥洛兹美医疗股价,奥洛兹美医疗股市,奥洛兹美医疗股票价格,奥洛兹美医疗股票交易,奥洛兹美医疗股票购买,奥洛兹美医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}